Genmab — September 2020
-
We have completed enrollment of a 133-patient Phase 1 clinical trial of Cami for the treatment of relapsed or refractory HL and NHL that has shown an 86.5% ORR and a 48.6% CRR in patients with HL at the initial dose for our pivotal Phase 2 clinical trial and a 44.0% ORR and an 8.0% CRR in a subset of patients with T-cell lymphoma as of April 2019.
-
GENMAB/SHB: KURSMÅL HÆVES TIL 2400 KR. FRA 1920 KR./ritzau/FINANS
-
and finally in exhibit 10.6 it reeds "The Parties agree to negotiate for a period ending on 31 August 2020 with the intent to agree in good faith on a non-binding term sheet that includes all key financial terms for a license agreement between the Parties whereby ADCT acquires Genmab’s share of the ADC"
-
Der er jo nærmest kunst med de streger. Ufatteligt så precist kursen følger retningen mod de 2550 som kunne være target inden næste retracement https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86954_Kunst.JPG
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
